<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412982</url>
  </required_header>
  <id_info>
    <org_study_id>Droege2015</org_study_id>
    <nct_id>NCT02412982</nct_id>
  </id_info>
  <brief_title>Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients</brief_title>
  <official_title>Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Air Force</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ
      between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed
      on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two
      enoxaparin dosing strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to determine if AT-III serum concentrations differ between patients
      with normal (&gt;= 0.1 IU/mL) versus subtherapeutic (&lt;0.1 IU/mL) anti-Xa trough concentrations
      when placed on enoxaparin 30 mg twice daily for venous thromboembolism (VTE) prophylaxis.
      Secondarily, this study will compare two enoxaparin dosing strategies: standard 30 mg twice
      daily and a dosing strategy based on trough anti-Xa values in high-risk trauma patients.

      Specific aims include: 1) to compare the extent of reduced AT-III activity between patients
      with trough anti-Xa &gt;= 0.1 IU/mL and &lt; 0.1 IU/mL upon initial assay; 2) to determine the
      proportion of patients who reach goal anti-Xa and the time to goal anti-Xa achievement
      between two interventional dosing strategies: enoxaparin 40 mg every 12 hours (with
      consideration to increase to 50 mg every 12 hours if recheck anti-Xa is not at goal) and
      enoxaparin 30 mg every eight hours; 3) to compare anti-Xa enoxaparin dosing strategies based
      on VTE, bleeding rates, transfusion requirements, drug discontinuation rate and
      bioaccumulation, and 4) to determine patient-specific factors that correlate to
      subtherapeutic anti-Xa such as serial AT-III activity, weight, body mass index, age,
      cumulative fluid administration, and thromboelastography (TEG).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial AT-III activity -- control group vs. other two groups combined</measure>
    <time_frame>After third dose of enoxaparin 30mg q12h, which will typically be on Day 2 of enoxaparin</time_frame>
    <description>Serum AT-III will be compared between the control group and the intervention group patients (combined) after the third dose of enoxaparin 30 mg every 12 hours once initiated at the discretion of the trauma service per current VTE prophylaxis protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Goal anti-Xa attainment / first repeat assessment</measure>
    <time_frame>At first repeat assessment, which will typically be on Day 2 of study</time_frame>
    <description>Proportion of patients reaching goal anti-Xa between the two active treatment arms at first repeat assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Traumatic Injury</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Serum anti-Xa &gt;= 0.1 IU/mL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with serum anti-Xa level &gt;= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 40 mg q12h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 30 mg q8h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with serum anti-Xa level &lt; 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 40 mg q12h</intervention_name>
    <description>Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.</description>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 40 mg q12h</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin 30 mg q8h</intervention_name>
    <description>Patients receive enoxaparin 30 mg every 8 hours.</description>
    <arm_group_label>Anti-Xa &lt;0.1 IU/mL:enoxaparin 30 mg q8h</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multi-system trauma

          -  Anticipated length of stay of at least 72 hours

          -  At high risk (risk adjustment profile [RAP] &gt;= 5) and initiated on enoxaparin 30 mg
             every 12 hours per VTE prophylaxis protocol

          -  No counterindication to trauma team VTE prophylaxis protocol (e.g., intracranial
             bleeding, incomplete spinal cord injury with hematoma within 24 hours post injury,
             ongoing hemorrhage, uncorrected coagulopathy, &gt;= grade IV liver or spleen injury,
             intraocular injury)

        Exclusion Criteria:

          -  Renal dysfunction (creatinine clearance &lt; 30 mL/min or on continuous renal replacement
             therapy)

          -  Weight &lt; 50 kg or &gt; 150 kg

          -  Platelet count &lt; 50,000

          -  Allergy to heparin or low molecular weight heparin

          -  On therapeutic anticoagulation on admission or requiring it within 24 hours of
             admission

          -  Isolated intracranial hemorrhage

          -  Known hyperbilirubinemia (serum bilirubin &gt; 6.6 mg/dL)

          -  Pregnancy

          -  Incarceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Molly Droege, PharmD</last_name>
    <phone>513-584-2126</phone>
    <email>Molly.Droege@UCHealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Droege, PharmD</last_name>
      <phone>513-584-2126</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Molly Droege</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist, Trauma, Surgery, and Orthopedics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

